Social Media Ideas for Abbv

HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.

A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie.

Abbott Laboratories (ABT) Dividend Stock Analysis

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: This diversified healt...

Should You Buy AbbVie Stock Before Oct. 30?

The healthcare company will release its third-quarter numbers later this month.

<![CDATA[Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic]]>

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Fri, 10/09/2026 - 07:09 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

<![CDATA[Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]>

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade

It would be hard for investors to replicate the company's return over the past decade.

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

Abaxx Technologies Inc. 2026 Q2 - Results - Earnings Call Presentation

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

Another potential blockbuster just joined AbbVie's drug portfolio.

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

These companies are committed to rewarding shareholders.

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.

Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside

Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.